STAT15h
An obesity startup wastes no time: With drugs in early testing, Metsera lines up manufacturing
The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...
FierceBiotech16h
After phase 1 data drop, Metsera allies with Amneal for supply of GLP-1, amylin weight loss candidates
With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...
Amneal To Become Metsera's Preferred Supply Partner For Developed Markets - Quick Facts
Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...
BioPharma Dive9h
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.
FierceBiotech7d
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to ...
Yahoo Finance7d
Metsera Reports Highly Competitive Results from Ongoing Trial of Novel, Potential Once-Monthly Injectable GLP-1 Receptor Agonist MET-097
Results include 7.5% reduction in body weight from baseline at day 36 Weight loss continued to at least 4 weeks after last dose administered MET-097, incorporating Metsera’s HALO™ platform ...
Investing4d
Wall Street SWOT: Amneal Pharmaceuticals stock rides wave of growth and innovation
Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a prominent player in the specialty pharmaceuticals sector, has been making waves in the market with its recent performance and strategic initiatives ...
Reuters8d
Amneal asks court to block Colorado's free allergy pen program
Sept 23 (Reuters) - Amneal Pharmaceuticals (AMRX.O), opens new tab has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to pharmacies. In a complaint ...
Seeking Alpha4d
AMRX Amneal Pharmaceuticals, Inc.
View Amneal Pharmaceuticals, Inc. (AMRX) current and estimated P/E ratio data provided by Seeking Alpha.
Investing1mon
Amneal receives FDA approval for generic propofol
BRIDGEWATER, N.J. - Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has announced the FDA approval of its Abbreviated New Drug Application (ANDA) for Propofol Injectable Emulsion in various dosages. This ...
Investing4d
Wall Street SWOT: Amneal Pharmaceuticals stock rides wave of growth and innovation
Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a prominent player in the specialty pharmaceuticals sector, has been making waves in the market with its recent performance and strategic initiatives. The ...